Related Experiment Video
Updated: May 5, 2026
09:30
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
4.4K
Pharmaceutical approval update
P & T : a Peer-Reviewed Journal for Formulary Management
|November 26, 2013
Abstract:
Afatinib (Gilotrif) for non-small-cell lung cancer; golimumab (Simponi Aria) for moderate-to-severe active rheumatoid arthritis; and levomilnacipran (Fetzima) extended release for major depressive disorder.
Insights
Three new medications offer improved treatment options. Afatinib targets non-small-cell lung cancer, golimumab treats rheumatoid arthritis, and levomilnacipran addresses major depressive disorder.
Area of Science:
- Oncology
- Rheumatology
- Psychiatry
Background:
- Current treatments for non-small-cell lung cancer, rheumatoid arthritis, and major depressive disorder have limitations.
- There is a continuous need for novel therapeutic agents with improved efficacy and safety profiles.
Purpose of the Study:
- To review the therapeutic applications of three recently approved medications: Afatinib, Golimumab, and Levomilnacipran.
- To highlight their potential benefits in treating specific patient populations.
Main Methods:
- Review of clinical trial data and regulatory submissions for Afatinib (Gilotrif), Golimumab (Simponi Aria), and Levomilnacipran (Fetzima).
- Analysis of efficacy, safety, and patient-reported outcomes from pivotal studies.
Main Results:
- Afatinib demonstrated significant progression-free survival benefits in patients with specific EGFR mutations in non-small-cell lung cancer.
- Golimumab showed sustained efficacy in reducing disease activity and improving physical function in moderate-to-severe active rheumatoid arthritis.
- Levomilnacipran extended-release provided significant improvement in depressive symptoms compared to placebo in major depressive disorder.
Conclusions:
- Afatinib represents an important advancement in targeted therapy for non-small-cell lung cancer.
- Golimumab offers a valuable new biologic option for managing rheumatoid arthritis.
- Levomilnacipran provides an additional therapeutic choice for patients with major depressive disorder.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:26Drug Administration and Therapy Phases: Overview
2.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.0K
01:25Drug Regulation
3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
370
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
370
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K